Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 211 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone HD Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

NCT01333462
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
NB-1008, Control
Biological · Other
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Immunity Against Pandemic Respiratory Virus

NCT00138281
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

NCT00258830
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

NCT00623181
View directory record Official record
Conditions
Influenza
Interventions
Fluzone: Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Grove City, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 1 Interventional

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

NCT01941758
View directory record Official record
Conditions
Central Nervous System Neoplasm
Interventions
trivalent influenza vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

NCT00389532
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

NCT00390884
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Fluzone®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Months to 14 Months
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
5
States / cities
Layton, Utah • Pleasant Grove, Utah • Provo, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influenza Immunity in Children

NCT02559505
View directory record Official record
Conditions
Influenza
Interventions
Seasonal IIV 0.25 mL dose, Natural influenza infection, Seasonal IIV 0.5 mL dose
Biological · Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Months to 8 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Responses Induced by Different Licensed Influenza Vaccines

NCT00902278
View directory record Official record
Conditions
Immune Response
Interventions
Flulaval, Fluvirin, Fluzone, Fluarix, Afluria
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo, HD quadrivalent influenza vaccine
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

NCT01232868
View directory record Official record
Conditions
Influenza
Interventions
trivalent Influenza vaccine (TIV)
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2007 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

NCT01427309
View directory record Official record
Conditions
Influenza
Interventions
High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
31,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
105
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 6, 2026, 10:01 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q, Fluzone Quadrivalent
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 6, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

NCT01946425
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 6, 2026, 10:01 AM EDT